Overview

A Study to Assess the Feasibility of Non-invasive Dried Blood Sampling

Status:
Enrolling by invitation
Trial end date:
2022-08-19
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, single-dose, 1-period study to compare EDG-5506 concentrations measured from venous and capillary blood sampling in healthy adult subjects. EDG-5506 is an investigational product designed to selectively modulate a fast skeletal muscle motor protein called myosin that is part of the contraction machinery of the damage-prone muscle fibers.
Phase:
Phase 1
Details
Lead Sponsor:
Edgewise Therapeutics, Inc.